Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by SFE Investment Counsel

SFE Investment Counsel cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,970 shares of the company’s stock after selling 900 shares during the quarter. SFE Investment Counsel’s holdings in Elanco Animal Health were worth $797,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Elanco Animal Health by 0.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 41,773,539 shares of the company’s stock valued at $1,230,231,000 after purchasing an additional 332,959 shares in the last quarter. BlackRock Inc. raised its stake in shares of Elanco Animal Health by 8.3% during the 1st quarter. BlackRock Inc. now owns 29,400,723 shares of the company’s stock worth $865,851,000 after buying an additional 2,242,381 shares during the last quarter. Amundi Asset Management US Inc. boosted its position in shares of Elanco Animal Health by 10.9% in the 1st quarter. Amundi Asset Management US Inc. now owns 13,087,232 shares of the company’s stock worth $385,421,000 after buying an additional 1,287,355 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its stake in Elanco Animal Health by 13.1% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 9,313,251 shares of the company’s stock valued at $274,276,000 after acquiring an additional 1,078,211 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Elanco Animal Health by 4.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,735,995 shares of the company’s stock valued at $257,276,000 after acquiring an additional 374,058 shares in the last quarter. Hedge funds and other institutional investors own 99.58% of the company’s stock.

ELAN has been the topic of a number of analyst reports. Cleveland Research raised Elanco Animal Health from an “underperform” rating to a “neutral” rating in a research report on Tuesday, June 15th. Zacks Investment Research downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating in a report on Friday, June 18th. Finally, Credit Suisse Group started coverage on shares of Elanco Animal Health in a research note on Thursday, August 5th. They set an “outperform” rating and a $38.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Buy” and a consensus target price of $37.75.

In other Elanco Animal Health news, major shareholder Elanco Animal Health Inc purchased 45,508,938 shares of the company’s stock in a transaction on Friday, August 27th. The shares were purchased at an average cost of $9.25 per share, for a total transaction of $420,957,676.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey N. Simmons acquired 16,850 shares of the stock in a transaction dated Wednesday, August 11th. The stock was acquired at an average cost of $29.70 per share, for a total transaction of $500,445.00. Following the purchase, the chief executive officer now directly owns 568,577 shares in the company, valued at $16,886,736.90. The disclosure for this purchase can be found here. In the last three months, insiders bought 45,528,788 shares of company stock valued at $421,545,062. Company insiders own 6.11% of the company’s stock.

Elanco Animal Health stock traded down $0.56 during midday trading on Wednesday, hitting $32.36. 32,224 shares of the stock were exchanged, compared to its average volume of 3,797,877. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.72 and a quick ratio of 1.00. Elanco Animal Health Incorporated has a 1 year low of $25.76 and a 1 year high of $37.49. The company has a 50 day moving average price of $33.79 and a two-hundred day moving average price of $33.05. The firm has a market cap of $15.31 billion, a P/E ratio of -21.95, a P/E/G ratio of 0.66 and a beta of 0.83.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Sunday, August 8th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. Elanco Animal Health had a negative net margin of 16.02% and a positive return on equity of 5.24%. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the firm earned ($0.09) EPS. The company’s revenue for the quarter was up 118.3% compared to the same quarter last year. As a group, analysts predict that Elanco Animal Health Incorporated will post 1.01 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health, Inc engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.

Featured Story: What are economic reports?

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.